Sarah Scagliarini, Medical Oncologist at AORN Cardarelli in Naples, shared on LinkedIn:
“Grateful and proud to have taken part in the XXVIII National Congress in Rome, ‘Innovazione Equa‘.
I had the honor of speaking in GU educational session on adjuvant therapies and oligometastatic management in renal cell carcinoma, a rapidly evolving field where treatment choices, patient selection and multidisciplinary team are more important than ever.
Thanks to the Commitee for the invitation and for the opportunity to share this moment with such a passionate GU community.
I had a privilege to attend the opening ceremony and listen to AIOM and ESMO presidents. I was also delighted to present a poster on an Italian study assessing the risk of recurrence after surgery in renal cell carcinoma, RECEPTOR trial and to discuss future projects and research perspectives on the multidisciplinary management of RCC.

And the journey continues: on December 9-10 in Naples we will host ‘Oligo Mets in RCC: an Italian multidisciplinary vision for a worldwide path‘, a national meeting bringing together medical oncologists, urologists, radiation oncologists, radiologists, pathologists, nuclear medicine specialists and patient advocates to discuss oligometastatic and oligoprogressive RCC. Registration is free.
I am honored to serve as Scientific Chair and can’t wait to welcome you at the Cardarelli Hospital!
A heartfelt thank you to all the colleagues, moderators and friends with whom I shared these days. Real progress in oncology happens when science, collaboration and equity go hand in hand.”

You can also read: Applying Metastatic Renal Cell Carcinoma Guidelines Across Resource Settings: From Recommendations to Deliverable Care.
